Intelligence Platform
Pharmaceutical Patent Intelligence
Patent intelligence for 30,257 US pharma patents (A61K/A61P) — expiration watchlists, recently granted filings, top assignees, and therapeutic area IP density linked to company and drug profiles.
Quick answer
NovaPharmaNews Patent Intelligence tracks 30,257 pharmaceutical patents from USPTO PatentsView with patent-cliff calendars, recently granted patents, top assignee rankings, and therapeutic-area IP hubs — cross-linked to company portfolios, drug INN profiles, pipeline programs, and news coverage.
Pharmaceutical patent activity at a glance
USPTO PatentsView index (A61K/A61P) cross-linked to 410 assignee companies — grants, expirations, therapeutic-area density, and patent-cliff signals for BD and IP teams.
Patent cliff — next 12 months
-
US 7078209
CAK inhibitors and uses thereof
granted -
US 7078412
Quinuclidine derivatives and medicinal compositions containing the same
granted -
US 7078033
Urinary tract tissue graft compositions and methods for producing same
granted -
US 7078223
Process for the preparation of pseudomonic acid a antibiotic by microbiological method
granted -
US 7078037
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
granted -
US 7078048
Method and compositions for treating rosacea
granted -
US 7078182
TAO protein kinase polypeptides and methods of use therefor
granted -
US 7078496
Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith
granted
New US pharma patents
-
WO 2026115454
ANTICORPS ANTI-CLAUDINE 18.2, FRAGMENTS DE LIAISON À L'ANTIGÈNE ET CONJUGUÉS ANTICORPS-MÉDICAMENT ASSOCIÉS ET MÉTHODES D'UTILISATION DANS UNE THÉRAPIE ANTICANCÉREUSE
granted -
US 20260152488
AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS
granted -
WO 2026114918
DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
WO 2026117667
DOSES DE TITRATION DE MARIDEBART CAFRAGLUTIDE
granted -
WO 2026114957
DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
WO 2026109631
UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER
granted -
WO 2026112386
COMPOSÉS D'OXOISOINDOLINYL PIPÉRIDINE-2,6-DIONE SUBSTITUÉS ET PROCÉDÉS DE DÉGRADATION DE PROTÉINES
granted -
US 20260146050
KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES
granted
Patents expiring by year
Patent activity by therapeutic area
Title-keyword classifier (v1) — each area links to its therapeutic-area IP hub.
Top patent applicants
Methodology
Data & provenance
Every figure on this page is derived from open USPTO data and refreshed on a recurring schedule. Patents are cross-linked to company and drug entity profiles wherever an assignee match exists.
Full methodology & data sources →- Source
- USPTO PatentsView
- Official US patent grant & assignment data
- Scope
- CPC A61K · A61P
- Pharmaceutical preparations & therapeutic activity
- Linkage
- Companies · Drugs
- Cross-referenced to entity profiles & pipelines
Answers
Frequently asked questions
What is the Pharmaceutical Patent Intelligence Platform?
It is NovaPharmaNews patent command center covering 30,257 US pharma-relevant patents — not just a directory. It includes expiration dashboards, recently granted and filed indexes, assignee rankings, and therapeutic-area patent hubs linked to company and drug entity profiles.
How do I track patent expirations (patent cliff)?
Use the Expiring Patents hub for patents expiring within 12 or 24 months, or browse by expiration year. Each patent links to applicant company portfolios and related drug profiles when available.
Where does patent data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews companies and drugs. See our data sources page for methodology and disclaimers.